Clinical Trials - EBS

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT02177721Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioNOT_YET_RECRUITINGPHASE42026-052035-122035-05
NCT05935917Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsCOMPLETEDPHASE12023-05-302023-09-272023-08-14
NCT05377255Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy AdultsCOMPLETEDPHASE12022-03-282022-05-102022-05-10
NCT05194358Study of SIAN Nasal Spray in Healthy AdultsCOMPLETEDPHASE12021-12-212023-10-132023-09-29
NCT05142306A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected AdultsCOMPLETEDPHASE12021-12-072022-05-312022-03-28
NCT05155319Universal Influenza A Vaccine in Healthy AdultsCOMPLETEDPHASE12021-12-012023-10-102023-10-10
NCT04661839A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy AdultsCOMPLETEDPHASE12020-12-242021-07-272021-07-27
NCT04067011Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyCOMPLETEDPHASE22019-08-122020-03-192020-03-05
NCT03877926VELOCITY: An Anthrax Vaccine Clinical StudyCOMPLETEDPHASE32019-03-112020-08-062020-08-06
NCT03624946Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)COMPLETEDPHASE12018-06-272019-03-062019-03-06
NCT03315104Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza ACOMPLETEDPHASE22017-11-172019-06-172019-06-17
NCT03160339A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047TERMINATEDPHASE12017-05-012017-11-272017-11-27
NCT02696291Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy SubjectsTERMINATEDPHASE12016-05-272017-03-022017-03-02
NCT02443623VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIVCOMPLETEDPHASE42015-092021-082021-07
NCT02771730Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected AdultsTERMINATEDPHASE12015-032017-022017-02
NCT02339155Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine AdsorbedCOMPLETEDPHASE42015-02-242017-06-062017-01-03
NCT02051062BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric PatientsENROLLING_BY_INVITATIONPHASE42014-102027-07-312027-07-31
NCT02061358Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy SubjectsCOMPLETEDPHASE12014-072015-092015-07
NCT01979406A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate VaccinesCOMPLETEDPHASE12013-112015-092014-10
NCT01770743A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsCOMPLETEDPHASE22013-012014-122014-02
NCT01753115Ciprofloxacin BioThrax Co-Administration StudyCOMPLETEDPHASE22012-122013-082013-08
NCT01491607Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsCOMPLETEDPHASE32011-112012-052012-05
NCT01263691Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy AdultsCOMPLETEDPHASE12010-122012-062012-05
NCT01158157VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVCOMPLETEDPHASE32010-09-132012-02-142012-02-14
NCT01202695Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)COMPLETEDPHASE12010-082011-062011-06
NCT01006798Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1COMPLETEDPHASE12009-102011-092011-09
NCT01311674Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)TERMINATEDPHASE32009-092011-03-112011-03-11
NCT00845650Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)COMPLETEDPHASE1, PHASE22009-022010-102010-10
NCT00679172Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy AdultsCOMPLETEDPHASE22008-052008-122008-12
NCT00636519Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB MuscleCOMPLETEDPHASE12008-022009-102009-10
NCT00448253Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human SerumCOMPLETEDPHASE12007-072008-092008-08
NCT00893516CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaTERMINATEDPHASE22007-052008-122008-10
NCT00360737Safety Study of 7 Botulinum Antitoxin Serotypes Derived From HorsesCOMPLETEDPHASE12006-072010-042006-12
NCT00877656HuMax-CD4 in Non-Cutaneous T-Cell LymphomaCOMPLETEDPHASE2, PHASE32005-082008-122006-01
NCT00053495Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationCOMPLETEDPHASE22003-012003-112003-06
NCT00053482Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsCOMPLETEDPHASE22003-012003-102003-04